VolitionRX (NYSEAMERICAN:VNRX) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

VolitionRX Limited (NYSEAMERICAN:VNRX)’s stock price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.81 and traded as low as $1.1550. VolitionRX shares last traded at $1.16, with a volume of 124,738 shares trading hands.

Analyst Ratings Changes

A number of equities analysts recently weighed in on VNRX shares. Citigroup cut VolitionRX to a “hold” rating in a report on Monday, April 20th. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. HC Wainwright cut their price objective on VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of VolitionRX in a research note on Thursday, June 18th. Finally, Benchmark reiterated a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, VolitionRX currently has a consensus rating of “Hold” and an average price target of $28.00.

VolitionRX Stock Performance

The company has a 50 day simple moving average of $1.81 and a 200 day simple moving average of $3.45. The company has a market capitalization of $10.01 million, a PE ratio of -0.28 and a beta of 1.12.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The firm had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.52 million. As a group, equities research analysts anticipate that VolitionRX Limited will post -2.4 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in VolitionRX during the 3rd quarter worth $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of VolitionRX in the second quarter worth about $52,000. Geode Capital Management LLC lifted its stake in shares of VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after buying an additional 85,816 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of VolitionRX in the fourth quarter worth about $28,000. Finally, Squarepoint Ops LLC acquired a new position in VolitionRX during the fourth quarter worth about $34,000. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.